Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia.

Abstract excerpt

We analysed the expression of the p53 gene in various clinical phases of chronic myelogenous leukaemia (CML) by quantitative reverse transcriptase (RT) polymerase chain reaction (PCR). Hemizygous expression of the wild-type p53 allele was observed in two samples showing the loss of one p53 allele, and affected p53 expression was associated with p53 allelic loss rather than the clinical phase of CML. In four...

Topics

• Alleles
• Base Sequence
• Chromosome Aberrations
• Chromosomes, Human, Pair 17
• Disease Progression
• Follow-Up Studies
• Gene Expression Regulation, Leukemic
• Genes, p53
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive